Kestra Medical Technologies (NASDAQ:KMTS) Stock Rating Raised to "Hold" at Wall Street Zen

Key Points

• Wall Street Zen upgraded Kestra Medical Technologies from “Sell” to “Hold.” Overall analyst sentiment remains a “Moderate Buy,” with five Buy, two Hold and one Sell rating and an average price target of $29.
• Kestra reported a quarterly loss of $0.75 per share, worse than the expected $0.61 loss, while revenue totaled $30.97 million. Analysts project a full-year loss of approximately $2.45 per share.
• Insiders have been selling shares: executives and directors sold nearly 400,000 shares worth about $10.8 million over the past three months, adding a potential concern despite the stock trading near its 52-week high.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) was upgraded by analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a note issued to investors on Saturday, Wall Street Zen reports.

A number of other analysts have also issued reports on the company. Oppenheimer began coverage on Kestra Medical Technologies in a research report on Tuesday, July 21st. They issued a "market perform" rating on the stock. Wolfe Research set a $30.00 price objective on Kestra Medical Technologies in a research note on Wednesday, July 15th. Royal Bank Of Canada set a $30.00 price objective on Kestra Medical Technologies in a research note on Tuesday, September 15th. Weiss Ratings upgraded Kestra Medical Technologies from a "sell (e+)" rating to a "sell (d-)" rating in a report on Wednesday, September 16th. Finally, Piper Sandler reaffirmed an "overweight" rating on shares of Kestra Medical Technologies in a research report on Tuesday, September 15th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $29.00.

Kestra Medical Technologies Stock Performance

Shares of KMTS stock opened at $29.69 on Friday. Kestra Medical Technologies has a 1-year low of $17.34 and a 1-year high of $31.06. The company has a 50-day moving average of $26.69 and a two-hundred day moving average of $23.82. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.33.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last released its quarterly earnings results on Monday, September 14th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.14). Kestra Medical Technologies had a negative net margin of 140.43% and a negative return on equity of 63.83%. The company had revenue of $30.97 million during the quarter. Equities analysts anticipate that Kestra Medical Technologies will post -2.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Kestra Medical Technologies

In other news, insider Brian Webster sold 51,900 shares of the stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $24.52, for a total value of $1,272,588.00. Following the sale, the insider directly owned 475,215 shares in the company, valued at approximately $11,652,271.80. This trade represents a 9.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Vaseem Mahboob sold 39,903 shares of Kestra Medical Technologies stock in a transaction on Wednesday, October 28th. The shares were sold at an average price of $30.48, for a total value of $1,216,243.44. Following the completion of the transaction, the chief financial officer owned 60,609 shares of the company's stock, valued at approximately $1,847,362.32. This trade represents a 39.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 399,694 shares of company stock worth $10,842,727. 5.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Kestra Medical Technologies

Large investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Kestra Medical Technologies during the third quarter worth about $353,000. Sterling Capital Management LLC increased its stake in shares of Kestra Medical Technologies by 834.0% during the third quarter. Sterling Capital Management LLC now owns 878 shares of the company's stock worth $25,000 after buying an additional 784 shares during the period. Corient Private Wealth LP raised its holdings in Kestra Medical Technologies by 284.2% in the second quarter. Corient Private Wealth LP now owns 60,614 shares of the company's stock valued at $1,542,000 after acquiring an additional 44,839 shares in the last quarter. California State Teachers Retirement System raised its holdings in Kestra Medical Technologies by 39.2% in the first quarter. California State Teachers Retirement System now owns 27,835 shares of the company's stock valued at $555,000 after acquiring an additional 7,844 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in Kestra Medical Technologies by 6.6% in the first quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company's stock valued at $1,844,000 after acquiring an additional 5,731 shares in the last quarter.

More Kestra Medical Technologies News

Here are the key news stories impacting Kestra Medical Technologies this week:

• Positive Sentiment: Kestra will participate in upcoming investor conferences, which could improve visibility for its wearable cardiac-monitoring and defibrillation platform and give management an opportunity to discuss growth plans. Kestra Medical Technologies to Participate in Upcoming Investor Conferences
• Neutral Sentiment: Analyst sentiment remains generally constructive, with five Buy ratings, two Holds and one Sell rating. Evercore initiated coverage with an Outperform rating and a $34 price target, while the reported average target is $29. However, the company remains unprofitable, and its latest quarterly loss exceeded consensus expectations.
• Negative Sentiment: Insider selling is the clearest near-term negative catalyst. CFO Vaseem Mahboob sold 79,500 shares across October 27–29 for approximately $2.41 million, reducing his direct holdings to 60,609 shares. Director Traci Umberger separately sold 30,000 shares for about $900,900. The transactions may raise concerns about insider confidence or encourage profit-taking after KMTS’s strong advance. Kestra Medical Technologies Insider Selling
• Negative Sentiment: Fundamentals remain a risk: Kestra reported a quarterly loss of $0.75 per share versus the expected $0.61 loss, with a negative net margin and analysts projecting a full-year loss of approximately $2.45 per share.

About Kestra Medical Technologies

Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient's heart rhythm and deliver a therapeutic shock when clinically necessary.

The company's platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.